Melanoma, version 2.2016 clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 4, 2016, Pages 450-473

  Coit, Daniel G ^a   Thompson, John A ^b   Algazi, Alain ^c   Andtbacka, Robert ^d   Bichakjian, Christopher K ^e   Carson, William E ^f   Daniels, Gregory A ^g   DiMaio, Dominick ^h   Ernstoff, Marc ⁱ   Fields, Ryan C ^j   Fleming, Martin D ^k   Gonzalez, Rene ^l   Guild, Valerie ^m   Halpern, Allan C ^a   Hodi, F Stephen ⁿ   Joseph, Richard W ^o   Lange, Julie R ^p   Martini, Mary C ^q   Materin, Miguel A ^r   Olszanski, Anthony J ^s   Ross, Merrick I ^t   Salama, April K ^u   Skitzki, Joseph ^v   Sosman, Jeff ^w   Swetter, Susan M ^x   Tanabe, Kenneth K ^y   Torres Roca, Javier F ^z   Trisal, Vijay ^aa   Urist, Marshall M ^ab   McMillian, Nicole ^ac   Engh, Anita ^ac   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j BARNES JEWISH HOSPITAL   (United States)

^k UNIVERSITY OF TENNESSEE   (United States)

^l UNIVERSITY OF COLORADO   (United States)

^m AIM   (United States)

ⁿ Dana Farber Brigham and Women's Cancer Center   (United States)

^o MAYO CLINIC   (United States)

^p JOHNS HOPKINS UNIVERSITY   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r YALE CANCER CENTER   (United States)

^s FOX CHASE CANCER CENTER   (United States)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^u DUKE CANCER INSTITUTE   (United States)

^v ROSWELL PARK CANCER INSTITUTE   (United States)

^w VANDERBILT INGRAM CANCER CENTER   (United States)

^x STANFORD CANCER INSTITUTE   (United States)

^y MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^z H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^aa CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^ab UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^ac NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENCYPRONE; IMIQUIMOD; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; PEGINTERFERON; ROSE BENGAL; TALIMOGENE LAHERPAREPVEC;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONSENSUS DEVELOPMENT; DRUG MEGADOSE; HUMAN; LASER SURGERY; LIMB PERFUSION; LOCAL THERAPY; LOW DRUG DOSE; MELANOMA; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY;

HUMANS; MELANOMA;

EID: 84964355523     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0051     Document Type: Article

References (175)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 2011;65:S17-25 e11-13.
3. National Cancer Institute. Surveillance Epidemiology and End Results. 2008. Available at: http://seer.cancer.gov/statfacts/html/melan.html#ref11. Accessed April 18, 2014.
4. Ekwueme DU, Guy GP, Jr., Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol 2011;65:S133-143.
5. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003;349:2233-2240.
6. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989;63:386-389.
7. Evans RD, Kopf AW, Lew RA, et al. Risk factors for the development of malignant melanoma-I: Review of case-control studies. J Dermatol Surg Oncol 1988;14:393-408.
8. Williams ML, Sagebiel RW. Melanoma risk factors and atypical moles. West J Med 1994;160:343-350.
9. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatol Surg 2006;32:481-492.
10. Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol 2014;70:847-857 e841-818.
11. Gordon D, Gillgren P, Eloranta S, et al. Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure: a retrospective population-based study. Melanoma Res 2015;25:348-356.
12. Green AC, Wallingford SC, McBride P. Childhood exposure to ultraviolet radiation and harmful skin effects: epidemiological evidence. Prog Biophys Mol Biol 2011;107:349-355.
13. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
14. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
16. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003;36:347-350.
17. Yonick D V, Ballo RM, Kahn E, et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg 2011;201:324-327; discussion 327-328.
18. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247-258.
19. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005;12:449-458.
20. Kibbi N, Kluger H, Choi JN. Melanoma: Clinical Presentations. Cancer Treat Res 2016;167:107-129.
21. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-4346.
22. Luke JJ, Triozzi PL, McKenna KC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 2015;28:135-147.
23. Shields CL, Kaliki S, Furuta M, et al. American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7731 Patients: The 2013 Zimmerman Lecture. Ophthalmology 2015;122:1180-1186.
24. Tacastacas JD, Bray J, Cohen YK, et al. Update on primary mucosal melanoma. J Am Acad Dermatol 2014;71:366-375.
25. Flaherty LE, Othus M, Atkins MB, et al. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma: an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol 2014;32:3771-3778.
26. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522-530.
27. National Institutes of Health. Study of pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III melanoma (MK-3475-054/KEYNOTE-054). Available at: http://clinicaltrials.gov/show/NCT02362594. Accessed January 25, 2016.
28. National Institutes of Health. Immunotherapy with nivolumab or nivolumab plus ipilimumab vs. double placebo for stage IV melanoma w. NED. Available at: http://clinicaltrials.gov/show/NCT02523313. Accessed January 25, 2016.
29. National Institutes of Health. Study to identify the optimal adjuvant combination scheme of ipilimumab and nivolumab in melanoma patients (OpACIN). Available at: http://clinicaltrials.gov/show/NCT02437279. Accessed January 25, 2016.
30. National Institutes of Health. Neoadjuvant and adjuvant checkpoint blockade in patients with clinical stage III or oligometastatic stage IVmelanoma. Available at: http://clinicaltrials.gov/show/NCT02519322. Accessed January 25, 2016.
31. National Institutes of Health. A phase I trial of a vaccine combining multiple class I peptides and montanide ISA 51VG with escalating doses of anti-PD-1 antibody nivolumab or ipilimumab with nivolumab for patients with resected stages IIIC/IV melanoma. Available at: http://clinicaltrials. gov/show/NCT01176474. Accessed January 25, 2016.
32. National Institutes of Health. Efficacy study of nivolumab compared to ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or stage IV melanoma (CheckMate 238). Available at: http://clinicaltrials.gov/show/NCT02388906. Accessed January 25, 2016.
33. National Institutes of Health. A study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in the adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection. (COMBI-AD). Available at: https://clinicaltrials.gov/ct2/show/NCT01682083. Accessed January 25, 2016.
34. National Institutes of Health. BrUOG 324: Adjuvant nivolumab and low dose ipilimumab for stage III and resected stage IV melanoma: a phase II Brown University Oncology Research Group trial. Available at: https://clinicaltrials.gov/ct2/show/NCT02656706. Accessed January 25, 2016.
35. National Institutes of Health. Trial of ipilimumab after isolated limb perfusion, in patients with metastases melanoma (ILP+/-IPI). Available at: https://clinicaltrials.gov/ct2/show/record/NCT02094391. Accessed January 25, 2016.
36. Lewis KD, Maio M, Mandala M, et al. BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419) [abstract]. ASCO Meeting Abstracts 2014;32: Abstract TPS9118.
37. National Institutes of Health. Ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Available at: https://clinicaltrials.gov/ct2/show/record/NCT01274338. Accessed January 25, 2016.
38. National Institutes of Health. Monoclonal antibody and vaccine therapy in treating patients with stage III or stage IV melanoma that has been removed during surgery. Available at: https://clinicaltrials.gov/ct2/show/record/NCT00025181. Accessed January 25, 2016.
39. Grossmann KF, Othus M, Tarhini AA, et al. SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma [abstract]. ASCO Meeting Abstracts 2015;33: Abstract TPS9085.
40. National Institutes of Health. Adjuvant dabrafenib (GSK2118436) in patients with surgically resected AJCC stage IIIC melanoma characterized by a BRAFV600E/K mutation. Available at: https://clinicaltrials.gov/ct2/show/record/NCT01682213. Accessed January 25, 2016.
41. National Institutes of Health. Neoadjuvant vemurafenib + cobimetinib in melanoma: NEO-VC. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02303951. Accessed January 25, 2016.
42. Wargo JA, Amaria RN, Ross MI, et al. Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma [abstract]. ASCO Meeting Abstracts 2015;33: Abstract TPS9091.
43. Rusciani L, Petraglia S, Alotto M, et al. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer 1997;79:2354-2360.
44. Pehamberger H, Soyer H P, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:1425-1429.
45. Grob JJ, Dreno B, De La Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905-1910.
46. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma: the Scottish study. Br J Cancer 2001;84:1146-1149.
47. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866-869.
48. Hancock B W, Wheatley K, Harris S, et al. Adjuvant interferon in highrisk melanoma: the AIM HIGH Study: United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:53-61.
49. Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390-402.
50. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.
51. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677.
52. Eggermont AM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer 2016;55:111-121.
53. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospectiverandomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008;19:1195-1201.
54. Hansson J, Aamdal S, Bastholt L, et al. Tw o different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with highrisk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 2011;12:144-152.
55. Agarwala SS, Lee SJ, Flaherty LE, et al. Randomized phase III trial of highdose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) [abstract]. J Clin Oncol 2011;29(Suppl 15): Abstract 8505.
56. Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009;27:939-944.
57. Mao L, Si L, Chi Z, et al. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alpha-2b in high-risk acral melanoma patients. Eur J Cancer 2011;47:1498-1503.
58. Payne MJ, Argyropoulou K, Lorigan P, et al. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol 2014;32:185-190.
59. Mohr P, Hauschild A, Trefzer U, et al. Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: final analysis of a randomized phase III dermatologic Cooperative Oncology Group Trial. J Clin Oncol 2015;33:4077-4084.
60. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-2783.
61. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-126.
62. Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012;30:3810-3818.
63. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
64. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b signifcantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.
65. McMasters KM, Egger ME, Edwards MJ, et al. Final results of the Sunbelt Melanoma Trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol 2016; pii: JCO633776. [Epub ahead of print].
66. ER Squibb & Sons, LLC. Prescribing information: YERVOY® (ipilimumab) injection, for intravenous use. 2015. Available at: http://dailymed.nlm. nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66&type=display. Accessed February 29, 2016.
67. Feng Y, Roy A, Masson E, et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013;19:3977-3986.
68. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and metaanalysis. BMC Med 2015;13:211.
69. Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9.
70. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
71. Chen JY, Hruby G, Scolyer RA, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008;113:2770-2778.
72. Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer 2014;120:1369-1378.
73. Guadagnolo BA, Prieto V, Weber R, et al. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. Cancer 2014;120:1361-1368.
74. Oliver DE, Patel KR, Switchenko J, et al. Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 2016;26:35-41.
75. Vongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck 2003;25:423-428.
76. National Institutes of Health. A randomised trial of postoperative radiation therapy following wide excision of neurotropic melanoma of the head and neck (RTN2). Available at: https://clinicaltrials.gov/ct2/show/record/NCT00975520. Accessed January 21, 2016.
77. Agrawal S, Kane JM, 3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009;115:5836-5844.
78. Pinkham MB, Foote MC, Burmeister E, et al. Stage III melanoma in the axilla: patterns of regional recurrence after surgery with and without adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2013;86:702-708.
79. Strojan P, Jancar B, Cemazar M, et al. Melanoma metastases to the neck nodes: role of adjuvant irradiation. Int J Radiat Oncol Biol Phys 2010;77:1039-1045.
80. Bibault JE, Dewas S, Mirabel X, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011;6:12.
81. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01):6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 2015;16:1049-1060.
82. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012;13:589-597.
83. Beadle BM, Guadagnolo BA, Ballo MT, et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2009;73:1376-1382.
84. Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006;66:1051-1055.
85. Mendenhall WM, Shaw C, Amdur RJ, et al. Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for localregional recurrence. Am J Otolaryngol 2013;34:320-322.
86. Hallemeier CL, Garces YI, Neben-Wittich MA, et al. Adjuvant hypofractionated intensity modulated radiation therapy after resection of regional lymph node metastases in patients with cutaneous malignant melanoma of the head and neck. Pract Radiat Oncol 2013;3:e71-77.
87. Conill C, Valduvieco I, Domingo-Domenech J, et al. Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. Clin Transl Oncol 2009;11:688-693.
88. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
89. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583-590.
90. Mintz AH, Kestle J, Rathbone M P, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78:1470-1476.
91. Patchell RA, Tibbs PA, Regine W F, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280:1485-1489.
92. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus wholebrain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-2491.
93. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009;10:1037-1044.
94. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-141.
95. Samlowski WE, Watson GA, Wang M, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 2007;109:1855-1862.
96. Hauswald H, Dittmar JO, Habermehl D, et al. Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiat Oncol 2012;7:130.
97. Yao KA, Hsueh EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg 2003;238:743-747.
98. Ridolfi L, Ridolfi R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology 2002;49:335-339.
99. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996;6:247-255.
100. Nasi ML, Lieberman P, Busam KJ, et al. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther 1999;5:139-144.
101. Hoeller C, Jansen B, Heere-Ress E, et al. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. J Invest Dermatol 2001;117:371-374.
102. Kaufman HL, Ruby CE, Hughes T, Slingluff CL, Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2014;2:11.
103. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780-2788.
104. Andtbacka RHI, Chastain M, Li A, et al. Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL) [abstract]. ASCO Meeting Abstracts 2015;33: Abstract TPS9094.
105. Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010;116:4139-4146.
106. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003;89:1620-1626.
107. Byers BA, Temple-Oberle CF, Hurdle V, McKinnon JG. Treatment of intransit melanoma with intra-lesional interleukin-2: a systematic review. J Surg Oncol 2014;110:770-775.
108. Temple-Oberle C F, Byers BA, Hurdle V, et al. Intra-lesional interleukin-2 therapy for in transit melanoma. J Surg Oncol 2014;109:327-331.
109. Ikic D, Spaventi S, Padovan I, et al. Local interferon therapy for melanoma patients. Int J Dermatol 1995;34:872-874.
110. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-990.
111. Krown SE, Hilal EY, Pinsky CM, et al. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer 1978;42:2648-2660.
112. Cohen MH, Jessup JM, Felix EL, et al. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 1978;41:2456-2463.
113. Mastrangelo MJ, Sulit HL, Prehn LM, et al. Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 1976;37:684-692.
114. Thompson J F, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol 2015;22:2135-2142.
115. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008;18:405-411.
116. Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 2011;104:711-717.
117. Garcia MS, Ono Y, Martinez SR, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res 2011;21:235-243.
118. Weide B, Eigentler TK, Pflugfelder A, et al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother 2011;60:487-493.
119. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, Carretero G. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2]. Actas Dermosifiliogr 2009;100:571-585.
120. Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974;180:635-643.
121. Van Jarwaarde JA, Wessels R, Nieweg OE, et al. CO2 laser treatment for regional cutaneous malignant melanoma metastases. Dermatol Surg 2015;41:78-82.
122. Kandamany N, Mahaffey P. Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. Lasers Med Sci 2009;24:411-414.
123. Gibson SC, Byrne DS, McKay AJ. Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg 2004;91:893-895.
124. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996;83:509-512.
125. Lingam MK, McKay AJ. Carbon dioxide laser ablation as an alternative treatment for cutaneous metastases from malignant melanoma. Br J Surg 1995;82:1346-1348.
126. Waters RA, Clement RM, Thomas JM. Carbon dioxide laser ablation of cutaneous metastases from malignant melanoma. Br J Surg 1991;78:493-494.
127. Hill S, Thomas JM. Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser. Eur J Surg Oncol 1993;19:173-177.
128. Turza K, Dengel LT, Harris RC, et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 2010;37:94-98.
129. Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002;205:135-138.
130. Kibbi N, Ariyan S, Faries M, Choi JN. Treatment of in-transit melanoma with intralesional bacillus Calmette-Guerin (BCG) and topical imiquimod 5% cream: a report of 3 cases. J Immunother 2015;38:371-375.
131. Heber G, Helbig D, Ponitzsch I, et al. Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy. J Dtsch Dermatol Ges 2009;7:534-536.
132. Miller AK, Dusing R, Meggison A, Aires D. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin. J Drugs Dermatol 2011;10:302-305.
133. Arbiser JL, Bips M, Seidler A, et al. Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases. J Am Acad Dermatol 2012;67:e81-83.
134. Shistik G, Prakash AV, Fenske NA, Glass LF. Treatment of locally metastatic melanoma: a novel approach. J Drugs Dermatol 2007;6:830-832.
135. Li X, Naylor MF, Le H, et al. Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. Cancer Biol Ther 2010;10:1081-1087.
136. Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs 2012;30:1641-1645.
137. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007;156:337-345.
138. Kidner TB, Morton DL, Lee DJ, et al. Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 2012;35:716-720.
139. Shi VY, Tran K, Patel F, et al. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series. J Am Acad Dermatol 2015;73:645-654.
140. Hinz T, Ehler LK, Bieber T, Schmid-Wendtner MH. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone. Eur J Dermatol 2013;23:532-533.
141. Kim YJ. Topical diphencyprone as an effective treatment for cutaneous metastatic melanoma. Ann Dermatol 2012;24:373-375.
142. Damian DL, Thompson JF. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg. Am J Clin Dermatol 2011;12:403-404.
143. Martiniuk F, Damian DL, Thompson JF, et al. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. J Drugs Dermatol 2010;9:1368-1372.
144. Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol 2007;56:869-871.
145. Damian DL, Shannon KF, Saw RP, Thompson JF. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 2009;50:266-271.
146. Harland CC, Saihan EM. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine. Lancet 1989;2:445.
147. Trefzer U, Sterry W. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma. Dermatology 2005;211:370-371.
148. Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol 2014;109:308-313.
149. Omlor G, Gross G, Ecker KW, et al. Optimization of isolated hyperthermic limb perfusion. World J Surg 1992;16:1117-1119.
150. Stehlin JS, Jr., Giovanella BC, De Ipolyi PD, Anderson RF. Results of eleven years' experience with heated perfusion for melanoma of the extremities. Cancer Res 1979;39:2255-2257.
151. Ko SH, Ueno T, Yoshimoto Y, et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 2006;12:289-297.
152. Lindner P, Doubrovsky A, Kam PC, Thompson J F. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-136.
153. Barbour A P, Thomas J, Suffolk J, et al. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 2009;16:3463-3472.
154. Di Filippo F, Garinei R, Giannarelli D, et al. Hyperthermic antiblastic perfusion in the treatment of locoregional spreading limb melanoma. J Exp Clin Cancer Res 2003;22:89-95.
155. Vrouenraets BC, Eggermont AM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001;27:390-395.
156. Thompson JF, Eksborg S, Kam PC, et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res 1996;6:267-271.
157. Creech O, Jr., Ryan R F, Krementz ET. Treatment of melanoma by isolationperfusion technique. J Am Med Assoc 1959;169:339-343.
158. Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994;4 Suppl 1:45-50.
159. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997;132:903-907.
160. Moreno-Ramirez D, De La Cruz-Merino L, Ferrandiz L, et al. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 2010;15:416-427.
161. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004;139:1237-1242.
162. Cornett WR, McCall LM, Petersen R P, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006;24:4196-4201.
163. Kroon HM. Treatment of locally advanced melanoma by isolated limb infusion with cytotoxic drugs. J Skin Cancer 2011;2011:106573.
164. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-247.
165. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer 2009;115:1932-1940.
166. Kroon HM, Lin DY, Kam PC, Thompson JF. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg 2009;249:1008-1013.
167. Kroon HM, Huismans AM, Kam PC, Thompson JF. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol 2014;109:348-351.
168. Beasley GM, Caudle A, Petersen R P, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009;208:706-715; discussion 715-707.
169. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009;16:2570-2578.
170. Lidsky ME, Turley RS, Beasley GM, et al. Predicting disease progression after regional therapy for in-transit melanoma. JAMA Surg 2013;148:493-498.
171. Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 2012;19:1637-1643.
172. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 2011;213:306-316.
173. Reintgen M, Reintgen C, Nobo C, et al. Regional therapy for recurrent metastatic melanoma confined to the extremity: hyperthermic isolated limb perfusion vs. isolated limb infusion. Cancers (Basel) 2010;2:43-50.
174. Sharma K, Beasley G, Turley R, et al. Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. Ann Surg Oncol 2012;19:2563-2571.
175. Steinman J, Ariyan C, Rafferty B, Brady MS. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. J Surg Oncol 2014;109:405-409.